Tumor Necrosis Factor Receptor Superfamily, Member 8 (TNFRSF8) ELISA Kits

The protein encoded by TNFRSF8 is a member of the TNF-receptor superfamily. Zusätzlich bieten wir Ihnen TNFRSF8 Antikörper (699) und TNFRSF8 Proteine (32) und viele weitere Produktgruppen zu diesem Protein an.

list all ELISA KIts Gen GeneID UniProt
TNFRSF8 943 P28908
TNFRSF8 21941 Q60846
TNFRSF8 25069 P97525
Direkt bei antikoerper-online bestellen
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Online bestellen
  • orders@antikoerper-online.de

Top TNFRSF8 ELISA Kits auf antikoerper-online.de

Showing 10 out of 66 products:

Katalog Nr. Reaktivität Sensitivität Bereich Bilder Menge Anbieter Lieferzeit Preis Details
Human 10pg/mL 156-10000 pg/mL Human CD30/TNFRSF8 PicoKine ELISA Kit standard curve 96 Tests Anmelden zum Anzeigen 4 bis 6 Tage
Maus < 10 pg/mL 10-3000 pg/mL 96 Tests Anmelden zum Anzeigen 2 bis 3 Tage
Ratte 0.135 ng/mL 0.31 ng/mL - 20 ng/mL 96 Tests Anmelden zum Anzeigen 13 bis 16 Tage
Schwein 0.469 ng/mL 0.781-50 ng/mL   96 Tests Anmelden zum Anzeigen 12 bis 14 Tage
Huhn 9.375 ng/mL 15.625-1000 ng/mL   96 Tests Anmelden zum Anzeigen 12 bis 14 Tage
Kaninchen 0.094 ng/mL 0.156-10 ng/mL   96 Tests Anmelden zum Anzeigen 12 bis 14 Tage
Meerschweinchen 1.875 ng/mL 3.125-200 ng/mL   96 Tests Anmelden zum Anzeigen 12 bis 14 Tage
Affe 0.469 ng/mL 0.781-50 ng/mL   96 Tests Anmelden zum Anzeigen 12 bis 14 Tage
  96 Tests Anmelden zum Anzeigen 15 bis 18 Tage
Rind (Kuh)
  96 Tests Anmelden zum Anzeigen 15 bis 18 Tage

Am meisten referenzierte TNFRSF8 ELISA Kits

  1. Human TNFRSF8 ELISA Kit für Sandwich ELISA - ABIN2859281 : Tosetti, Venè, Camodeca, Nuti, Rossello, DArrigo, Galante, Ferrari, Poggi, Zocchi: Specific ADAM10 inhibitors localize in exosome-like vesicles released by Hodgkin lymphoma and stromal cells and prevent sheddase activity carried to bystander cells. in Oncoimmunology 2018 (PubMed)

Weitere ELISA Kits für TNFRSF8 Interaktionspartner

Human Tumor Necrosis Factor Receptor Superfamily, Member 8 (TNFRSF8) Interaktionspartner

  1. CD30+ diffuse large B-cell lymphoma has characteristic clinicopathological features mutually exclusive with MYC gene rearrangement and negatively associated with BCL2 protein expression.

  2. Data suggest that CD4+ T cell-associated HIV-1 RNA is often highly enriched in cells expressing CD30; cells expressing this marker considerably contribute to total pool of transcriptionally active CD4+ lymphocytes in individuals on suppressive anti-retroviral drug therapy; CD30 may be a marker of residual, transcriptionally active HIV-1 infected cells in blood and in gut-associated lymphoid tissue.

  3. The stable elevation in classical Hodgkin lymphoma risk with elevated levels of sCD30 and IL6 across 4 or more years prior to diagnosis may also reflect a B-cell-stimulatory environment that promotes the genesis of these cancers.

  4. extranodal NK/T-cell lymphoma, nasal type(ENKTL) is the most common type of mature T-cell and NK-cell lymphoma diagnosed at our institution. CD30 is frequently expressed in ENKTL and represents a therapeutic target; however, it may not be a prognostic marker.

  5. This study suggests that in patients with CD30+ lymphoproliferative disorders, an aggressive clinical course cannot be defined by the presence of TP63 rearrangements, as was recently shown in systemic ALK negative anaplastic large cell lymphoma.

  6. Data suggest that Brentuximab Vedotin (SGN-35) damaged CD30 ligand (CD30L)-immune cells through CD30 extracellular vesicles (EVs).

  7. median FoxP3+ Treg count was higher in CD30+ than in CD30- posttransplant lymphoproliferative disorders, 3.0 vs 0

  8. Variant histology is common in pediatric NLPHL, especially types C and E, which are associated with IgD expression. Type C variant histology and possibly type D are associated with decreased EFS, but neither IgD nor CD30 are adverse features. Variant histology may warrant increased surveillance, but did not affect overall survival.

  9. Expression of CD30 in patients with both DLBCL and other aggressive B-cell lymphomas and the absence of MYC oncogene-driven proliferation in the majority of these tumors suggests that brentuximab may be a particularly effective form of targeted therapy in the subset of patients with high CD30 expression.

  10. Prevalence of the CD30 (Ki-1) antigen in human solid tumors was summarized.

  11. Higher serum sCD30 levels were associated with an increased risk of bacterial infection after kidney transplantation.

  12. CD30 expression was detected in up to 25% of cases of diffuse large B-cell lymphoma and was more frequent in tumors without MYC rearrangement. CD30 expression was not associated with overall survival in R-EPOCH-treated de novo DLBCL patients.

  13. CD30 facilitates phosphorylation of heat shock factor 1, activates heat shock promoter element, and induces heat shock protein (HSP) 90.

  14. this study shows that polyclonal and allogeneic stimulation induced higher levels of CD30 transcripts in end-stage renal disease patients compared to control patients

  15. CD30 expression was not associated with prognosis in our cohort of de novoDLBCL, including in patients who received aggressive chemotherapy. CD30 expression and MYC rearrangement were mutually exclusive in de novoDLBCL.

  16. Case Report: CD30 positive lymphomatoid papulosis arising in association with cutaneous amyloidosis in a patient with multiple myeloma.

  17. The heterogeneity of CD30 expression in refractory or relapsed peripheral T-cell lymphoma patients indicates the likelihood for better response for patients with strong CD30 expression by tumor cells.

  18. CD30 may be useful as a prognostic marker in rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) treated DLBCLs, indicating favorable outcomes in a Chinese population.

  19. this review is focused on the role of CD30 receptor and p53 as novel targets for therapy in ALK+ ALCL, and also provides an update on their potential involvement in ALK+ ALCL pathogenesis

  20. Most angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma-not otherwise specified express variable levels of CD30.

TNFRSF8 Antigen-Profil

Beschreibung des Gens

The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. This receptor is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.

Genbezeichner und Symbole assoziert mit TNFRSF8

  • TNF receptor superfamily member 8 (TNFRSF8) Antikörper
  • tumor necrosis factor receptor superfamily, member 8 (Tnfrsf8) Antikörper
  • TNF receptor superfamily member 8 (Tnfrsf8) Antikörper
  • Cd30 Antikörper
  • D1S166E Antikörper
  • Ki Antikörper
  • Ki-1 Antikörper
  • TNFRSF8 Antikörper

Bezeichner auf Proteinebene für TNFRSF8

CD30L receptor , Ki-1 antigen , cytokine receptor CD30 , lymphocyte activation antigen CD30 , tumor necrosis factor receptor superfamily member 8 , Tumor necrosis factor superfamily member 8 , tumor necrosis factor superfamily, member CD30 , tumor necrosis factor receptor superfamily, member 8 , tumor necrosis factor receptor superfamily member 8-like

943 Homo sapiens
21941 Mus musculus
25069 Rattus norvegicus
395090 Gallus gallus
457960 Pan troglodytes
487438 Canis lupus familiaris
614780 Bos taurus
722773 Macaca mulatta
100385465 Callithrix jacchus
100579424 Nomascus leucogenys
Ausgewählte Anbieter für TNFRSF8 (TNFRSF8) ELISA Kits
Haben Sie etwas anderes gesucht?